Functional FCGR3A 158 V/F and IL-6-174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Young Ho | - |
dc.contributor.author | Bae, Sang-Cheol | - |
dc.contributor.author | Song, Gwan Gyu | - |
dc.date.accessioned | 2021-09-05T04:28:01Z | - |
dc.date.available | 2021-09-05T04:28:01Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-10 | - |
dc.identifier.issn | 0172-8172 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/97188 | - |
dc.description.abstract | The aim of this study was to investigate whether the Fc gamma receptor 3A (FCGR3A) 158 V/F and interleukin-6 (IL-6) promoter -174 G/C polymorphisms can predict the response to biologic-based therapy in patients with rheumatoid arthritis (RA). We conducted a meta-analysis of studies on the association between the FCGR3A V/F polymorphism or the IL-6 -174 C/G polymorphism and non-responsiveness to biologic therapy in RA patients. A total of 10 studies involving 1,427 patients were considered. These studies consisted of seven studies on the FCGR3A polymorphism and three studies on the IL-6 polymorphism. Meta-analysis showed no association between the FCGR3A VV+VF genotype and non-responders to biologic therapy [odds ratio (OR) 0.881, 95 % confidence interval (CI) 0.505-1.537, p = 0.655]. However, stratification by biologic type indicated an association between the FCGR3A VV+VF genotype and non-responders to rituximab (OR 0.566, 95 % CI 0.373-0.857, p = 0.007), but no association was found in non-responders to tumor necrosis factor (TNF)-blockers (OR 1.337, 95 % CI 0.869-2.056, p = 0.186). Meta-analysis revealed no association between the IL-6 CC+CG genotype and non-responders to the biologics (OR 3.233, 95 % CI 0.766-13.64, p = 0.110). However, an association was found between the IL-6 CC+CG genotype and non-responders to anti-TNF therapy (OR 8.030, 95 % CI 1.807-33.68, p = 0.006). This meta-analysis demonstrates that FCGR3A V allele carriers show a better response to rituximab, and individuals carrying the IL-6 -174 C allele show a poorer response to anti-TNF therapy for RA. Genotyping for these polymorphisms may be a useful tool for predicting the response to biologics with respect to personalized medicine. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER HEIDELBERG | - |
dc.subject | ANTITUMOR NECROSIS FACTOR | - |
dc.subject | SYSTEMIC-LUPUS-ERYTHEMATOSUS | - |
dc.subject | GENE PROMOTER POLYMORPHISM | - |
dc.subject | GENOME SCAN METAANALYSIS | - |
dc.subject | ALPHA-BLOCKING AGENTS | - |
dc.subject | TNF-ALPHA | - |
dc.subject | MONOCLONAL-ANTIBODY | - |
dc.subject | INTERLEUKIN-6 IL-6 | - |
dc.subject | TREATMENT OUTCOMES | - |
dc.subject | FC-RECEPTORS | - |
dc.title | Functional FCGR3A 158 V/F and IL-6-174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young Ho | - |
dc.contributor.affiliatedAuthor | Song, Gwan Gyu | - |
dc.identifier.doi | 10.1007/s00296-014-3015-1 | - |
dc.identifier.scopusid | 2-s2.0-84918827039 | - |
dc.identifier.wosid | 000342455600009 | - |
dc.identifier.bibliographicCitation | RHEUMATOLOGY INTERNATIONAL, v.34, no.10, pp.1409 - 1415 | - |
dc.relation.isPartOf | RHEUMATOLOGY INTERNATIONAL | - |
dc.citation.title | RHEUMATOLOGY INTERNATIONAL | - |
dc.citation.volume | 34 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1409 | - |
dc.citation.endPage | 1415 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | ANTITUMOR NECROSIS FACTOR | - |
dc.subject.keywordPlus | SYSTEMIC-LUPUS-ERYTHEMATOSUS | - |
dc.subject.keywordPlus | GENE PROMOTER POLYMORPHISM | - |
dc.subject.keywordPlus | GENOME SCAN METAANALYSIS | - |
dc.subject.keywordPlus | ALPHA-BLOCKING AGENTS | - |
dc.subject.keywordPlus | TNF-ALPHA | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | INTERLEUKIN-6 IL-6 | - |
dc.subject.keywordPlus | TREATMENT OUTCOMES | - |
dc.subject.keywordPlus | FC-RECEPTORS | - |
dc.subject.keywordAuthor | Rheumatoid arthritis | - |
dc.subject.keywordAuthor | Biologics | - |
dc.subject.keywordAuthor | FCGR3A | - |
dc.subject.keywordAuthor | IL-6 polymorphisms | - |
dc.subject.keywordAuthor | Non-responsiveness | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.